Stocks · News reference
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Entrada Therapeutics (NASDAQ:TRDA) reported quarterly losses of $(1.01) per share which beat the analyst consensus estimate of $(1.09) by 7.34 percent. This is a 2.88 percent increase over losses of $(1.04) per share
Read original at benzingaFiled: 2026-08-05 AccNo: 0001689375-26-000052 Size: 243 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgarEntrada Therapeutics, Inc. (NASDAQ:TRDA) today announced that an independent Data Monitoring Committee (DMC), per study protocol, has reviewed all available safety and PK data from the eight participants enrolled in
Read original at benzinga